150 related articles for article (PubMed ID: 30959137)
21. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
22. Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer.
Su YY; Sun L; Guo ZR; Li JC; Bai TT; Cai XX; Li WH; Zhu YF
J Ovarian Res; 2019 Jan; 12(1):6. PubMed ID: 30670062
[TBL] [Abstract][Full Text] [Related]
23. Is sphere assay useful for the identification of cancer initiating cells of the ovary?
Martínez-Serrano MJ; Caballero-Baños M; Vilella R; Vidal L; Pahisa J; Martínez-Roman S
Int J Gynecol Cancer; 2015 Jan; 25(1):12-7. PubMed ID: 25365589
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer.
Wilczyński M; Żytko E; Danielska J; Szymańska B; Dzieniecka M; Nowak M; Malinowski J; Owczarek D; Wilczyński JR
Arch Gynecol Obstet; 2018 Mar; 297(3):741-748. PubMed ID: 29335784
[TBL] [Abstract][Full Text] [Related]
25. Circulating miRNA Profiling in Plasma Samples of Ovarian Cancer Patients.
Penyige A; Márton É; Soltész B; Szilágyi-Bónizs M; Póka R; Lukács J; Széles L; Nagy B
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540229
[TBL] [Abstract][Full Text] [Related]
26. Serum miR-1181 and miR-4314 associated with ovarian cancer: MiRNA microarray data analysis for a pilot study.
Ruan L; Xie Y; Liu F; Chen X
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():31-38. PubMed ID: 29353130
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological and prognostic value of CD24 expression in breast cancer: a meta-analysis.
Liu G; Liu GX; Fang Y; Cao ZY; Du HH; Fu J; Qian K
Int J Biol Markers; 2017 May; 32(2):e182-e189. PubMed ID: 28315505
[TBL] [Abstract][Full Text] [Related]
28. The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features.
Xu S; Xu P; Wu W; Ou Y; Xu J; Zhang G; Li J; Xu G
Curr Pharm Des; 2014; 20(11):1888-95. PubMed ID: 23888941
[TBL] [Abstract][Full Text] [Related]
29. Role of CD24 in anoikis resistance of ovarian cancer cells.
Li YH; Sun X; Wang HB
J Huazhong Univ Sci Technolog Med Sci; 2015 Jun; 35(3):390-396. PubMed ID: 26072079
[TBL] [Abstract][Full Text] [Related]
30. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
Lancaster JM; Sayer RA; Blanchette C; Calingaert B; Konidari I; Gray J; Schildkraut J; Schomberg DW; Marks JR; Berchuck A
Int J Gynecol Cancer; 2006; 16(4):1529-35. PubMed ID: 16884361
[TBL] [Abstract][Full Text] [Related]
31. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
32. CD24 gene polymorphism--a novel prognostic factor in esophageal cancer.
Sadot E; Kraus S; Stein M; Naboishchikov I; Toledano O; Kazanov D; Arber N; Kashtan H
Int J Biol Markers; 2014 Mar; 29(1):e49-54. PubMed ID: 24474454
[TBL] [Abstract][Full Text] [Related]
33. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
[TBL] [Abstract][Full Text] [Related]
34. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
35. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity.
Madhavan B; Yue S; Galli U; Rana S; Gross W; Müller M; Giese NA; Kalthoff H; Becker T; Büchler MW; Zöller M
Int J Cancer; 2015 Jun; 136(11):2616-27. PubMed ID: 25388097
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Lee YK; Park NH; Lee H
Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
[TBL] [Abstract][Full Text] [Related]
37. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
38. Exosome-derived miRNAs and ovarian carcinoma progression.
Vaksman O; Tropé C; Davidson B; Reich R
Carcinogenesis; 2014 Sep; 35(9):2113-20. PubMed ID: 24925027
[TBL] [Abstract][Full Text] [Related]
39. Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study.
Lea J; Sharma R; Yang F; Zhu H; Ward ES; Schroit AJ
Oncotarget; 2017 Feb; 8(9):14395-14407. PubMed ID: 28122335
[TBL] [Abstract][Full Text] [Related]
40. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
